Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma

26 Sept 2014

Abstract excerpt

Basal cell carcinomas (BCCs) and a subset of medulloblastomas are characterized by loss-of-function mutations in the tumor suppressor gene, PTCH1. PTCH1 normally functions by repressing the activity of the Smoothened (SMO) receptor. Inactivating PTCH1 mutations result in constitutive Hedgehog pathway activity through uncontrolled SMO signaling. Targeting this pathway with vismodegib, a novel SMO inhibitor,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer and Skin Lesions
Share to Genetic and rare skin diseases.
Share to Hedgehog Signaling Pathway Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25306392
DOI: 10.1016/j.molonc.2014.09.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinomaPMID 25306392Read ↗

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.Semantic proximity Read ↗

Smoothened variants explain the majority of drug resistance in basal cell carcinoma.Semantic proximity Read ↗

Targeting the hedgehog pathway to treat basal cell carcinoma.Semantic proximity Read ↗

Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.Semantic proximity Read ↗

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.Semantic proximity Read ↗

[Metastatic basal cell carcinoma with a SMO gene mutation. A case report].Semantic proximity Read ↗

Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.Semantic proximity Read ↗

Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.Semantic proximity Read ↗

Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothened AntagonistsSemantic proximity Read ↗

Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastomaSemantic proximity Read ↗

Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.Semantic proximity Read ↗

Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult MedulloblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.